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Summary Isolated limb perfusion (ILP) with tumour necrosis factor alpha (TNF-a) and melphalan has shown
impressive results in patients with irresectable soft tissue sarcomas and stage III melanoma of the extremities.
The mechanisms of the reported in vivo synergistic anti-tumour effects of TNF-a and melphalan are not
precisely understood. We have developed an ILP model in the rat using a non-immunogenic sarcoma in which
similar in vivo synergy is observed. The aim of this present study was to analyse the morphological substrate for
this synergistic response of TNF-cx in combination with melphalan to shed more light on the pathomechanisms
involved. Histology of the tumours from saline- (n = 14) and melphalan-treated (n = 11) rats revealed apparently
vital tumour cells in over 80% of the cross-sections. Interstitial oedema and coagulation necrosis were observed
in the remaining part of the tumour. Haemorrhage was virtually absent. TNF-oa (n =22) induced marked
oedema, hyperaemia, vascular congestion, extravasation of erythrocytes and haemorrhagic necrosis (20-60%
of the cross-sections). Oedema and haemorrhage suggested drastic alterations of permeability and integrity of
the microvasculature. Using light and electron-microscopy, we observed that haemorrhage preceded generalised
platelet aggregation. Therefore, we suggest that the observed platelet aggregation was the result of the
microvascular damage rather than its initiator. Remarkably, these events hardly influenced tumour growth.
However, perfusion with the combination of TNF-a and melphalan (n = 24) showed more extensive
haemorrhagic necrosis (80-90% of the cross-sections) and revealed a prolonged remission (mean 11 days)
in comparison with the other groups of rats. Electron microscopical analysis revealed similar findings as
described after TNF-ax alone, although the effects were more prominent at all time points after perfusion. In
conclusion, our findings suggest that the enhanced anti-tumour effect after the combination of TNF-a with
melphalan results from potentiation of the TNF-oa-induced vascular changes accompanied by increased vascular
permeability and platelet aggregation. This may result in additive cytotoxicity or inhibition of growth of
residual tumour cells.
Keywords: tumour necrosis factor alpha; melphalan; isolated limb perfusion; sarcoma; platelets
Isolated limb perfusion (ILP) with TNF-a and melphalan has
shown impressive results in patients with irresectable soft
tissue sarcomas and stage III melanoma of the extremities
(Lienard et al., 1992, 1994). ILP involves isolation of the
diseased limb, its connection to a heart-lung machine and
the administration of a triple drug regimen at 39-40°C (mild
hyperthermia) based on the reported synergism of TNF-a
with melphalan and interferon-y (IFN-y) (Eggermont et al.,
1993). The rationale of ILP is to improve the response rate
by increasing the drug concentration while avoiding systemic
toxicity. Morphological and immunohistochemical analysis of
biopsies from patients after ILP suggested that the tumour
microvasculature is a major target for TNF-a and melphalan.
We and others have shown previously that events such as von
Willebrand factor release, platelet aggregation and congestion
concentrated on the tumour vasculature, leaving the normal
tissues largely unaffected (Renard et al., 1994, 1995).
However, the mechanisms of in vivo synergistic anti-tumour
effects of TNF-ax and melphalan are still not understood
precisely.
As the drug regimen in patients contains at least two
experimental drugs, it does not allow us to reach definitive
conclusions about the relative contribution of TNF-a and
melphalan. Therefore, an experimental isolated perfusion
model on sarcoma in the rat was devised. Rats transplanted
with a non-immunogenic BN sarcoma in the hind leg were
treated by isolated limb perfusion (Marquet et al., 1983;
Benckhuijsen et al., 1982; Manusama et al., 1994). Using this
model, we recently showed in vivo synergism between TNF-a
and melphalan in ILP with a tumour response resembling the
clinical results (Manusama et al., 1996). ILP in the rat with
saline or 50 ,ug of TNF-ax alone had no impact on tumour
growth, and 40 ,ug of melphalan only temporarily inhibited
tumour growth. In the group perfused with the combination
of both TNF-c and melphalan, complete regression occurred
in 75% of the rats. The aim of the present work was to study
in this rat model the histopathological changes after ILP with
TNF-oc alone, melphalan alone and the combination of both
drugs and so shed more light on the pathomechanisms
involved. We hereby present evidence at the light and
electron-microscopical level that the histopathological
changes observed in the tumours after perfusion with TNF-
a alone were augmented by addition of the chemotherapeutic
agent.
Materials and methods
Animals
Male rats of the inbred BN strain, weighing 250-300 g, were
obtained from Harlan-CPB (Austerlitz, The Netherlands).
They were fed a standard laboratory diet (Hope Farms,
Woerden, The Netherlands) and kept under standard
laboratory conditions. The specific protocol was approved
by the committee on animal research of The Erasmus
University, Rotterdam, The Netherlands.
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The spontaneous BN 175 sarcoma transplantable to BN rats
was used (Marquet et al., 1983). This BN 175 sarcoma is a
rapidly growing and metastasising tumour. Immunogenicity
of the tumour was determined by inoculating rats with
tumour, excising the tumour, reinoculating the rats with the
same tumour and measuring the percentage of rats that
show tumour take. According to this method, described by
Prehn and Main (1957), BN 175 sarcoma is non-
immunogenic.
Isolated limb perfusion (ILP)
The tumour model and perfusion procedure were described
previously by Manusama et al. (1994, 1996). Briefly, small
fragments of BN 175 sarcoma (3-5 mm) were implanted in
the right hind limb subcutaneously. Perfusion was performed
in rats with established tumours with a mean diameter of
13.6+3.0 mm at 10.3+3.0 days after transplantation.
Hypnorm (10 mg ml-' fluanisone, 0.315 mg ml-' fentanylci-
trate: Janssen Pharmaceutica, Tilburg, The Netherlands) was
given i.v. for anaesthesia. A warm water mattress was applied
around the leg to maintain the temperature of the leg at 38-
39°C. The temperature of the leg was measured during the
perfusion by a naked bead type K probe fixed with its tip at
the convexity of the tumour and connected to a digital
thermometer (Mera Benelux, Berkel-Enschot, The Nether-
lands). The femoral artery and vein were approached by a
parainguinal incision and cannulated in the distal direction
with silastic tubing (artery: 0.30 mm inner diameter, 0.64 mm
outer diameter, vein: 0.64 mm inner diameter, 1.19 mm outer
diameter) (Dow, Corning, MI, USA). Collaterals of the
femoral vessels were occluded during the perfusion by the
application of a tourniquet in the groin. The tourniquet was
fixed at the inguinal ligament. Isolation time commenced
when the tourniquet was tightened. The circuit included an
oxygenation chamber (5 ml syringe; Braun Melsungen,
Germany) and a roller pump (type 505U; Watson Marlow,
Falmouth, UK). The perfusion was started by circulating
5 ml of Haemaccel (Behring Pharma, Amsterdam, The
Netherlands) resulting in a haemoglobin content of approxi-
mately 1 mmol 1` (mean 0.94+0.16). Melphalan (Wellcome,
London, UK) and TNF-ax (recombinant human TNF-a,
(Boehringer Ingelheim, Germany) were added as boluses to
the oxygenation resevoir. The treatment modalities are
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specified in Table I. The roller pump recirculated the
perfusate at a flow rate of 2.4 ml min-', which was sufficient
to maintain the partial pressure of oxygen, (p02) in the
tumour (Manusama et al., 1994). A washout was done at the
end of the perfusion with 2.0 ml of oxygenated Haemaccel.
The perfusion time was 30 min, including the washout. After
the procedure, the femoral vessels of the perfused limb were
ligated, which was allowed by restoration of the collateral
circulation. In the BN rat, the presence of collateral
circulation was demonstrated by a continuous venous return
when the femoral artery was ligated. Furthermore, oxygen
pressure in the tumour after ligation of the femoral vessels
was equivalent to that before ligation as described in a
previous study (Manusama et al., 1994).
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Figure 1 Degree of tumour necrosis after various treatment
regimens, expressed as percentage of the cross-section.Synergistic effects of TNF-a and melphalan
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Histological procedure
The tumours were excised with a rim of skin whereas the
muscle layer formed the deep resection margin. After
removal, the tumours were carefully cut in two almost equal
parts in dorsoventral direction. In 42 out of 76 rats one half
of the specimen was directly frozen in liquid nitrogen and
stored at -80°C until further processing and the other half
was divided into a peripheral part (containing the margin
tumour/pre-existing tissues) and a central part (containing
Figure 2 Paraffin sections of ILP-treated rat BN sarcoma, haematoxylin-eosin (HE) stained. (a) Overview of tumour and skin,
24 h after ILP with saline (magnification x 40). (b) Tumour, 24 h after ILP with saline (magnification x 200, detail from a). A blood
vessel is marked by an arrow and a mitotic figure by an arrowhead. (c) Overview of tumour and skin, 24h after ILP with melphalan
(magnification x 40). (d) Tumour, 24h after ILP with melphalan (magnification x 200, detail from c). (e) Overview of tumour and
skin, 24h after ILP with TNF-a (magnification x 40). (f) Tumour, 24h after ILP with TNF-ax (magnification x 100, detail from le).
Haemorrhage is marked by an arrow. (g) Overview of tumour and skin, 24h after ILP with the combination of TNF-a and
melphalan (magnification x 40). (h) Tumour, 24h after ILP with the combination of TNF-at and melphalan (magnification x 100,
detail from g). A blood vessel with a thrombus is marked by an arrow. s, Skin; t, tumour; n, necrosis; h, haemorrhage.tumour from the centre of the lesion) and prepared for
ultrastructural analysis. In 34 rats, both parts of the specimen
were formalin-fixed and embedded in paraffin. Cyrostat and
paraffin sections (4 pm) were haematoxylin-eosin stained.
Tumour necrosis was assessed by conventional histological
criteria; the percentage of non-viable tumour was estimated
in a representative histological section that included both the
central and the peripheral borders of the tumour bed and
expressed as percentage of the cross-section and scored in the
following categories: 0-20%, 21-50%, 51-80% and 81-
100%. The extent and character ofthe inflammatory infiltrate
was evaluated. The slides were read by two different
observers. In case of disagreement, consensus was reached
during joined re-examination.
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were noted in the tumour and at the interface of tumour with
dermal and subcutaneous tissues (not shown). Margination of
polymorphonuclear cells was apparent in dilated vessels next
to the tumour (not shown).
Melphalan Slices of tumours treated with melphalan
generally appeared solid and grey. Microscopical examina-
tion 24 h after melphalan showed a highly cellular tumour
mass (Figure 2c and d). Over 80% of the cut surface of the
tumour sections consisted of apparently vital tumour tissue.
Interstitial oedema, scattered areas of necrosis and individual
cell necrosis were observed in the remaining part of the
tumour. Necrosis was of the coagulative type. Tumour cells
with fragmented nuclei were encountered, compatible with
apoptosis. Haemorrhage was virtually absent. The tumour
Immunohistochemistry
Platelet aggregation was visualised by immunohistochemistry
on representative cryostat sections that included both the
central and the peripheral border of the tumour bed, 4, 12
and 24 h after perfusion with saline (n =4), melphalan (n =4),
TNF-a (n =6) and TNF-cx in combination with melphalan
(n =6). Cryostat sections (4 pm) were stained using a two-
step immunoperoxidase procedure, as described previously
(Nooijen et al., 1996), using MAb PLl-1/Er 21 (Baghus et al.,
1989) directed against rat platelets, kindly provided by Dr E
De Heer (University Hospital Leiden, Leiden, The Nether-
lands), and using PAb RaHu FVIII, recognising von
Willebrand factor (VWF) from the Central Laboratory of
the Netherlands Red Cross Blood Transfusion Service (CLB).
As secondary antibodies, peroxidase-conjugated swine anti-
rabbit Ig and rabbit anti-mouse Ig were used (Dako, 1:100),
preabsorbed with 5% normal rat serum. The peroxidase label
was visualised by incubation with 3-amino-9-ethylcarbazole
as a substrate. The semiquantitative grading used was as
follows: no change (o), sporadic event (±), focal event (+),
generalised event (+ +).
Electron microscopy
Small tissue fragments from the central and the peripheral part
of the tumour were immediately fixed for 24 h in 2.5%
glutaraldehyde with 0.1 mol sodium cacodylate. The material
was post-fixed in 1% osmium sodium cacodylate buffer for 1 h
at room temperature (RT), dehydrated and embedded in epon
812. One micron sections were cut and stained with toluidine
blue for light microscopy. Ultrathin sections were cut with a
diamond knife (Drukker, Cuijk, The Netherlands) on an
ultramicrotome (ReichertJung,Vienna, Austria). Theultrathin
sections were contrasted for 15 min with uranyl 3%, followed
by a 3 min treatment with lead citrate, and examined and
photographed with a JEOL 1200 EX/II electron microscope
(Tokyo, Japan) at 60 kV. The electron microscopical analysis
focused on the microvascular changes.
Results
Histology
The semiquantitative assessment of tumour necrosis in a
representative histological section after the different treatment
modalities at various time points following the perfusion is
shown in Figure 1.
Controls Slices of tumours from saline-treated and un-
treated control rats showed the presence of solid and grey
tumour mass between the epidermis and the muscle of the
right hind limbs. Histology revealed individual cell necrosis
and scattered areas of confluent necrosis, both of the
coagulative type. Over 80% of the tumour consisted of
apparently vital tumour tissue with several mitotic figures and
showing a high vascularity (Figure 2a and b). Apoptotic
bodies were seen incidentally. Hyperaemia and oedema were
observed locally. Scattered mononuclear inflammatory cells
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Figure 3 Semiquantitative assessment of platelet aggregation
after various treatment regimens, in a representative cryostat
section. 0, No change; ±, sporadic event; +, focal event; + +,
generalised event.
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mass was hardly infiltrated by polymorphonuclear cells, but
scattered mononuclear inflammatory cells were observed in
the centre and at the margin.
TNF-cx Slices of tumours from animals treated with TNF-
a generally appeared red and soft in comparison with the
solid grey tumours in the untreated and saline-treated
controls. Histology of the material harvested 2 h after ILP
with TNF-cx revealed vascular congestion, marked inter-
stitial oedema and focal extravasation of erythrocytes (not
shown). These vascular effects were most obvious in the
tumour margins and in the adjacent connective tissue. Four
hours after ILP, TNF-oa induced a red discoloration with
diffuse haemorrhage and marked vascular congestion
(defined as dilated vessels compacted with erythrocytes as
a sign of hyperaemia and/or haemostasis) compared with
the controls, both in the central parts of the tumour and at
the interface of the tumour with dermal tissues (not
shown). Twenty-four hours after TNF-a treatment,
haemorrhage and tumour cell necrosis could be observed
centrally and constituted 20-60% of the tumour (Figure 2e
and f). Vascular congestion and thrombi were often seen.
Histologically vital-appearing tumour cells were situated at
the margins next to normal skin. In and around areas with
haemorrhage, scattered mononuclear inflammatory cells
could be observed. Infiltration of the tumour by poly-
morphonuclear cells was seen in four rats (two rats 4 h
after ILP and two rats 24 h after ILP) (not shown).
Combination of TNF-cx and melphalan Slices of tumours
from animals treated with the combination of drugs generally
appeared red and soft. Microscopic examination 2 h after
ILP revealed marked vascular congestion and interstitial
oedema along with extravasation oferythrocytes (not shown).
Scattered mononuclear inflammatory cells were present in the
tumour and at the periphery. Margination of polymorpho-
nuclear cells was observed in a few cases in some dermal
vessels next to the tumour. At 4 h after perfusion, vascular
congestion and haemorrhage were generally seen (not
shown). Twelve hours after ILP these effects were intensified
with increased disintegration of tumour cells, showing
apparent nuclear pyknosis or fragmentation. These effects
were more prominent centrally in the tumour. By 24 h,
approximately 80-90% of the tumour had undergone
extensive necrosis. Cell debris, oedema, haemorrhage,
thrombi and mononuclear inflammatory cells were observed
(Figure 2g and h). In three rats (out of 24), a moderate
infiltration of the tumour by polymorphonuclear cells was
observed (not shown). In addition, the epidermis overlying
the area ofcentral necrosis was necrotic (Figure 2g). A rim of
viable tumour cells persisted at the margins next to the
dermis (Figure 2g and h) and seemed to be responsible for
the outgrowth of the tumour over the subsequent days.
Immunohistochemistry
PLI-I (platelets) The semiquantitative assessment of
platelet aggregation in a representative histological section
after various treatment modalities at various time points
following perfusion is shown in Figure 3. Sections of the
saline-treated rats 4, 12 and 24 h after perfusion showed
sporadic (±) intravascular PLI-I staining in the tumour
(Figure 4a). PLI-I staining 4, 12 and 24 h after melphalan
treatment varied from sporadic (±) to focal (+) (Figure 4b).
PL1-1 staining in the vessels outside the tumour was
sporadically observed. TNF-a-treated rats showed intravas-
cular PLI-I staining focally (+) in the tumour 4 h after
treatment (not shown). Generalised (+ +) PLl-I staining was
observed 12 and 24 h after TNF-oa-perfusion (Figure 4c).
PLI-I staining was also observed in vessels adjacent to the
tumour. Perfusion treatment with TNF-a in combination
with melphalan showed intravascular PLI-I staining focally
(+) in the tumour in sections 4 h after perfusion (not
shown). In all sections 12 and 24 h after perfusion with TNF-
Figure 4 Immunohistochemical staining with the platelet marker PL1-I on frozen sections of rat BN sarcoma. (a) Overview of
tumour, 12h after ILP with saline (magnification x 50) showing sporadic (±) PL1-1 staining. (b) Overview of tumour, 12h-after
ILP with melphalan (magnification x 50) showing focal (+) PL1-l staining. (c) Overview of tumour, 12h after ILP with TNF-a
(magnification x 50) showing generalised (+ +) PLI-I staining. (d) Overview of tumour, 12h after ILP with TNF-a and melphalan
(magnification x 50) showing marked generalised (+ +) PLI-1 staining. c, Tumour centre; p, periphery of the tumour.Synergistic effects of TNF-a and melphalan
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a in combination with melphalan, marked generalised (+ +)
PLI-1 staining was observed (Figure 4d), and also in vessels
adjacent to the tumour (Figure 4e).
rHu FVIII (von Willebrand factor) We found that this
antibody was not suitable for the analysis as possible leakage
of von Willebrand factor by the endothelium after perfusion
treatment in our animal model, as the intensity of the
endothelial staining was low in combination with a diffuse
background staining.
Electronmicroscopy
The tumours contained numerous small vessels. Intratumoral
vessels at the periphery of the control tumours and after
saline perfusion revealed a continuous endothelial cell lining,
often surrounded by pericytes. Smooth muscle cells were
only occasionally found. Centrally in the tumour, few
degenerated endothelial cells were observed in areas with
oedema and haemorrhage, suggestive of vascular leakage.
These findings were not accompanied by a marked
inflammatory cell infiltrate. Platelets were found adherent
to the vessel wall. The ultrastructural findings after ILP with
melphalan (40 ,ug) resembled those described after saline
perfusion.
After perfusion with TNF-a (50 ,ug), marked intercellular
oedema was seen. Increased haemorrhage, both centrally
and at the periphery (2, 4 and 12 h after ILP), suggested
vascular leakage (Figure 5b). Intratumoral and peritumoral
vessels showed marked erythrostasis (Figure 5a and 5f). At
the periphery of the tumours, the vessels loaded with
erythrocytes revealed signs of endothelial cell degeneration,
i.e. electron-lucent cytoplasm and swollen mitochondria
(Figure 5a and c). Extensive aggregation of platelets was
observed both in the intratumoral vessels and just outside
the tumour, but merely mural and not occlusive (Figure 5e).
Increased haemorrhage and intravascular platelet aggrega-
tion were observed 24 h after perfusion with TNF-a in the
tumour, with disintegration of the endothelial cells (Figure
5d), only in the tumour centre, with extensive oedema and
tumour cell necrosis. These phenomena were not accom-
panied by a marked inflammatory cell infiltrate.
Ultrastructural analysis of sections after perfusions with
TNF-ax and melphalan revealed similar findings as described
after TNF-a alone, although the findings were more prominent
atall timepointsafterperfusion. Because ofthis similarity, only
the ultrastructural changes after TNF-a are shown.
Discussion
Tumour necrosis factor-a (TNF-a) in combination with
interferon-y (IFN-y) and melphalan in an isolated limb
perfusion setting resulted in a high remission rate in patients
with irresectable soft tissue sarcomas (Lienard et al., 1992;
Eggermont et al., 1992). An overall response rate of 88%
with a limb salvage of 87% was reported (Eggermont et al.,
1993). However, perfusion with TNF-a alone proved to be
ineffective (Posner et al., 1994). The mechanism of tumour
regression by the combination of TNF-a and the
chemotherapeutic agent melphalan, in vivo, is not precisely
understood but was proposed to follow a dual targeting
pathway (Lejeune, 1995; Renard et al., 1995). The first
target is represented by the tumour microvasculature. TNF-a
was assumed to induce endothelial cell damage, leading to
von Willebrand factor release (VWF). Released VWF may
play a role in the adhesion between platelet and the
damaged endothelium or the denuded vessel wall. As a
consequence, the blood flow is impaired, leading to
congestion and oedema. The second target is represented
by the tumour cells themselves, which are increasingly
subjected to the cytotoxic effects of melphalan in a hypoxic
environment.
In order to study the impact of the individual drugs on
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Figure 5 Ultrastructural microvascular changes after ILP with
TNF-a. (a) Blood vessel at the periphery of the tumour, 12h after
ILP, loaded with erythrocytes and lined by degenerated
endothelial cells (magnification x4000). (b) Erythrocyte extra-
vasation in the periphery of the tumour, 4h after ILP
(magnification x5000). (c) Detail of the endothelial cell in
Figure 3a, showing signs of degeneration. A swollen mitochon-
drion is marked by an arrow (magnification x6000). (d) Blood
vessel in the tumour centre, 12h after ILP showing disturbed
integrity of the endothelial cell (marked by an arrow)
(magnification x2500). Inset, high power image of part of the
cytoplasm of the endothelial cell showing merely intact
mitochondria. (e) Platelet aggregation in a blood vessel in the
periphery of the tumour, 12h after ILP (magnification x 6000). (f)
Blood vessel in the dermis adjacent to the tumour, 12h after ILP,
loaded with erythrocytes. E, erythrocytes; EC, endothelial cell;
BM, basement membrane; P, platelet.
tumour regression we used an experimental model of sarcoma
in the rat. We previously showed an in vivo synergism
between two relatively ineffective doses of TNF-a (50 ,ug) and
melphalan (40 jig) in this rat model, with a tumour response
resembling the clinical response (Manusama et al., 1996). The
present study was set up to analyse the morphological
substrate for this synergistic response employing light
microscopic, immunohistochemical and electron microscopic
methods. Histopathological analysis of the transplanted non-
immunogenic BN sarcoma after ILP with TNF-a alone
showed similar findings as reported by Asher et al. (1987) in06-0 Synergistic effects of TNF-x and melphalan
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a non-immunogenic MCA-102 murine sarcoma after TNF-a
i.v. injection and closely resembled the effects described for
endotoxin-induced histopathological features (van de Wiel et
al., 1989; Kuper et al., 1985, 1986). TNF-oa induced oedema,
hyperaemia, vascular congestion, extravasation of erythro-
cytes and haemorrhagic necrosis (20-60%) (Regenass et al.,
1987; MacPherson and North, 1986; Sato et al., 1986).
Remarkably, these events hardly influenced tumour diameter
and tumour growth in our rat ILP model. Increased doses of
only TNF-a did not lead to an increased anti-tumour effect;
even with doses of 100 ,ug in all seven rats, progressive
disease was observed (unpublished results). Furthermore,
when using TNF-a intravenously in toxic doses, no effect on
tumour growth was noted in the same model (unpublished
results). Therefore, the combination with melphalan is
necessary to obtain an effective anti-tumour response. On
the other hand, at higher doses of melphalan alone,
regression occurred with a gradual disappearance of the
tumour without haemorrhagic necrosis (Manusama et al.,
1996). Combination with TNF-a lowered the effective dose of
melphalan and introduced a vascular component into the
mechanism of action, characterised by extensive haemor-
rhagic necrosis.
Oedema and haemorrhage suggested dramatic alterations
of permeability and integrity of microvascular endothelial
cells. The cause of the vascular stasis and congestion is not
clear, but it may be related to a direct cytotoxic effect of
TNF-a on endothelial cells (Sato et al., 1986). A direct toxic
effect and activation of procoagulant activity in tumour
endothelial cells with subsequent thrombus formation might
be responsible for haemorrhagic necrosis (Gerlach et al.,
1989; Watanabe et al., 1988; Nawroth et al., 1988;
Shimomura et al., 1988). Using light and electron micro-
scopy, we observed, however, that haemorrhage preceded
generalised platelet aggregation without fusion of platelets
with endothelial cells (Grau et al., 1993). Therefore, we
suggest that the observed platelet aggregation was the result
of the endothelial damage rather than the initiator. These
findings are consistent with those observed in sequential
biopsies of human lesions after ILP (Renard et al., 1995). In
most cases, the centre of the tumour seemed to be more
vulnerable to the treatment than the periphery. Aberrant
branching and twisting of the vasculature and abnormal high
pressure in the interstitial matrix of the tumour centre, with
pre-existing increased vascular permeability, may have led to
an uneven distribution of the drugs and uneven distribution
ofthe vascular changes observed (Jain, 1987a,b). The vascular
changes in the tumour margins, accompanied with stasis, may
have contributed to a decreased blood flow out ofthe tumour
with development of central haemorrhagic necrosis.
The anti-tumour activity and necrosis induced by the
combination of intratumorally injected TNF-oa and IFN-y
systemically were studied by de Kossodo et al. (1995) in a
breast cancer xenograft model. Recent study in an
experimental ILP model revealed almost similar findings
using the combination of TNF-a and melphalan. Similar
potentiation of the anti-tumour activity were observed,
associated with vascular congestion and accumulation of
platelets in areas of vascular damage. Whether polymorpho-
nuclear leucocytes contributed to the vascular damage in our
rat ILP model is not clear. A polymorphonuclear cell
infiltrate in the tumour after perfusion with TNF-a and
with the combination generally was not observed, whereas
haemorrhage and necrosis were a consistent finding. The
exact role of polymorphonuclear leucocytes in the anti-
tumour effect needs to be analysed in future studies using
perfusions of granulocytopenic rats. Although it is difficult to
derive the dynamics of vascular damage and tumour
regression from static images, our observations support the
interpretation of Regenass et al. (1987) that the TNF-a-
induced increase in permeability of the endothelial cells leads
to increased blood viscosity. In this view, the decreasing
tumour blood flow is further impaired by intravascular
platelet aggregation, resulting in a sustained haemostasis and
finally in haemorrhagic infarction. The increased vascular
permeability together with a reduced blood flow out of the
tumour may have led to increased intratumoral concentra-
tions of melphalan or prolongation of its effect. Our findings
indicate that it is important to measure the effects on vascular
permeability. Experiments to determine vascular permeability
changes and melphalan concentrations in the tumours are in
progress.
Perfusion with the combination of TNF-c and melphalan
increased both the occurrence and extent of the haemor-
rhagic necrosis. Necrosis was not confined to the tumour
cells but also involved microvascular cells, both in the
tumour and in the adjacent dermis. The potentiation of the
TNF-ac-induced vascular effects by melphalan might be
explained by additive cytotoxicity direct to the vascular
endothelium (Regenass et al., 1987; Kachel and Martin,
1994; Alexander et al., 1987) and/or increased endothelial
cell reactivity to platelets (Bertomen et al., 1990). Our
(histo)pathological findings support the proposition by
Lejeune (1995) that the combination of TNF-a and
melphalan works through a dual targeting system. In this
view, the first target is represented by the tumour
vasculature and the second one by the tumour cells
themselves. However, the proposed granulocyte-mediated
endothelial damage does not seem to be a conditio sine
qua non and therefore should be studied further. In
conclusion, our findings suggest that the enhanced anti-
tumour effect after the combination of TNF-oa with
melphalan results from potentiation of the TNF-oc-induced
vascular changes accompanied by increased permeability.
This may result in additive cytotoxicity or inhibition of
growth of residual tumour cells.
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